Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · regulatory

US FDA sets up board to oversee drug exclusivity determinations

16 October 2026 · By · Wire by Fusion42

Published

16 October 2026

Topic

regulatory

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at reuters.com →

◆ Verified

Fusion42 · 17 October 2026 · Fusion42 review

The US FDA's Center for Drug Evaluation and Research (CDER) has established an exclusivity board to oversee and advise on drug exclusivity decisions, focusing on new chemical entity exclusivity, clinical trial exclusivity, and biological product exclusivity to improve clarity and consistency.

This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it between 16 Oct 2026 and 17 Oct 2026.

◆ ◆ The Wire takeaway

You must prepare for increased scrutiny on drug exclusivity claims as the FDA centralises oversight and standardises decisions. This change opens a critical advisory window to influence exclusivity policies before they solidify.

◆ Coverage

2 sources · first reported 16 Oct 2026 · latest 17 Oct 2026

◆ Related on Wire

◆ Topics

BiotechFDAdrug-exclusivityCDERregulatory-boardpharmaceuticals